Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study Of Nivolumab and Relatlimab In Advanced Mismatch Repair Deficient Cancers Resistant To Prior PD-(L)1 Inhibitor, Including Pancreatic Cancer

Summary

The purpose of this phase II study is to evaluate the safety and efficacy of Nivolumab and Relatimab in patients with microsatellite instability high (MSI-H) solid tumors, including pancreatic cancer prior to receiving PD-(L)1 therapy.

General Information

NCT#: NCT03607890
Study ID: J18102
Trial Phase: Phase II

Trial Sponsor: Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: Nivolumab, Relatinib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search